CUMBERLAND PHARMACEUTICALS, INC.
Biotech · Public
YTR107, a small molecule inhibitor that blocks NPM1 recruitment to DNA double-strand breaks to enhance radiation therapy efficacy in lung cancer
- Grants
- $2.2M
- 3 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 9 granted · 31 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes | $224,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting DNA damage response pathways for the treatment of advanced lung cancer | $924,071 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting DNA damage response pathways for the treatment of advanced lung cancer | $1,070,134 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1819 | KYRON, INC. | — | $3.0M |
| 1820 | MBQ PHARMA INC. | — | $4.2M |
| 1821 | NEUROPATHIX, INC. | — | $1.3M |
| 1822 | CUMBERLAND PHARMACEUTICALS, INC. | — | — |
| 1823 | Biohaven Environmental Solutions, LLC | — | $1.4M |
| 1824 | Discgenics, Inc. | — | $870K |
| 1825 | Prairie Pharms, LLC | — | $455K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods For The Prevention Or Treatment Of Anthrax Infectionapplication
- Injectable Ibuprofen Formulationapplication
- Methods For The Prevention Or Treatment Of Anthrax Infectionapplication
- Injectable Ibuprofen Formulationapplication
- Injectable Ibuprofen Formulationgranted
- Thromboxane Receptor Antagonists in AERD/Asthmagranted
- Injectable Solution Of Norepinephrineapplication
- Thromboxane Receptor Antagonists in AERD/Asthmaapplication
- Thromboxane Receptor Antagonists in AERD/Asthmaapplication
- Stabilized Statin Formulationsapplication
- Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonistsapplication
- Stabilized Statin Formulationsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.